Radboudumc at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Radboudumc brings 2 presentations to ASH 2026 in New Orleans. Its program covers glycans as a cause of and therapeutic target in myeloid cancers, and calreticulin mutations in inherited high platelet counts. It also joins advice for trainees moving into faculty roles.
| Organization | ASH 2026 Attendance |
|---|---|
Radboudumc Nijmegen, Netherlands | |
Academic medical centre of Radboud University in Nijmegen, the Netherlands. | Talk Sun Dec 13 4:30pm–5:45pm Glycans in the Pathogenesis and as a Therapeutic Target in Myeloid Malignancies How sugar chains on growth factor receptors shape their function, drive chemotherapy resistance and immune evasion, and could be drug targets in myeloid cancers. Poster Sun Dec 13 6:00pm–8:00pm Session Mon Dec 14 12:15pm–1:15pm |
Find decision makers at Radboudumc
Tell us what you sell and we’ll find the people at Radboudumc most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction